HUE053697T2 - Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása - Google Patents

Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása

Info

Publication number
HUE053697T2
HUE053697T2 HUE16766294A HUE16766294A HUE053697T2 HU E053697 T2 HUE053697 T2 HU E053697T2 HU E16766294 A HUE16766294 A HU E16766294A HU E16766294 A HUE16766294 A HU E16766294A HU E053697 T2 HUE053697 T2 HU E053697T2
Authority
HU
Hungary
Prior art keywords
neoplastic cell
converting
growth factor
receptor agonist
factor receptor
Prior art date
Application number
HUE16766294A
Other languages
English (en)
Inventor
Omar F Zouani
Veronika Gocheva
Original Assignee
Histide Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histide Ag filed Critical Histide Ag
Publication of HUE053697T2 publication Critical patent/HUE053697T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE16766294A 2015-09-17 2016-09-15 Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása HUE053697T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219728P 2015-09-17 2015-09-17

Publications (1)

Publication Number Publication Date
HUE053697T2 true HUE053697T2 (hu) 2021-07-28

Family

ID=56936411

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16766294A HUE053697T2 (hu) 2015-09-17 2016-09-15 Neoplasztikus sejt nem neoplasztikus sejtté alakításához használt gyógyszerészeti együttes, mely egy növekedésifaktor-receptor agonistából és egy adhéziós fehérjeinhibitorból áll, és ezek felhasználása

Country Status (17)

Country Link
US (1) US20190290729A1 (hu)
EP (3) EP3875102A1 (hu)
JP (2) JP7236134B2 (hu)
KR (1) KR20180050744A (hu)
CN (1) CN109715190A (hu)
AU (1) AU2016323407A1 (hu)
CA (1) CA2998297A1 (hu)
DK (1) DK3349776T3 (hu)
ES (1) ES2862103T3 (hu)
HR (1) HRP20210441T1 (hu)
HU (1) HUE053697T2 (hu)
IL (2) IL299622A (hu)
LT (1) LT3349776T (hu)
PL (1) PL3349776T3 (hu)
SG (1) SG10201913366QA (hu)
SI (1) SI3349776T1 (hu)
WO (1) WO2017046227A2 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311298A1 (en) 2015-08-25 2018-02-08 Histide Ag Compounds for inducing tissue formation and uses thereof
KR20180052726A (ko) * 2015-09-17 2018-05-18 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2019023634A1 (en) 2017-07-28 2019-01-31 Circle Pharma, Inc. CYCLATIVE RELEASE OF PEPTIDE COMPOUNDS
CN116204770B (zh) * 2022-12-12 2023-10-13 中国公路工程咨询集团有限公司 一种用于桥梁健康监测数据异常检测的训练方法及装置

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
DE19748688C2 (de) * 1997-04-22 2001-09-06 Hans Georg Graeber Membransystem zur gesteuerten Geweberegeneration bei Erkrankungen des Zahnhalteapparates
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
WO2005030933A2 (en) * 2003-09-24 2005-04-07 Genera Doo Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
PT1844337E (pt) * 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
CA2615491C (en) * 2005-07-19 2016-11-29 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
US7998740B2 (en) * 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
GB0615129D0 (en) * 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
BRPI0813630A2 (pt) * 2007-07-27 2019-09-24 Facet Biotech Corp combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)
ES2699532T3 (es) * 2011-03-23 2019-02-11 Univ California Métodos y composiciones para mejorar la terapia antiangiogénica con anti-integrinas
PT2981822T (pt) * 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento

Also Published As

Publication number Publication date
IL299622A (en) 2023-03-01
EP3875102A1 (en) 2021-09-08
IL258131B2 (en) 2023-06-01
IL258131A (en) 2018-05-31
EP3349776B1 (en) 2020-12-30
LT3349776T (lt) 2021-03-25
CN109715190A (zh) 2019-05-03
SG10201913366QA (en) 2020-02-27
PL3349776T3 (pl) 2021-08-02
SI3349776T1 (sl) 2021-04-30
WO2017046227A3 (en) 2017-06-29
EP3906932A2 (en) 2021-11-10
HRP20210441T1 (hr) 2021-04-30
KR20180050744A (ko) 2018-05-23
AU2016323407A1 (en) 2018-04-19
JP2018536623A (ja) 2018-12-13
CA2998297A1 (en) 2017-03-23
WO2017046227A2 (en) 2017-03-23
EP3906932A3 (en) 2021-12-01
ES2862103T3 (es) 2021-10-07
EP3349776A2 (en) 2018-07-25
JP7236134B2 (ja) 2023-03-09
US20190290729A1 (en) 2019-09-26
DK3349776T3 (da) 2021-03-22
JP2023027372A (ja) 2023-03-01

Similar Documents

Publication Publication Date Title
ZA201700211B (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
EP3497086A4 (en) AMINO PYRIMIDINE SSAO INHIBITORS
EP3484478A4 (en) HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY
EP3250229A4 (en) Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
EP3145505A4 (en) N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
IL258131A (en) A pharmaceutical composition containing a growth receptor agonist and an adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and its uses
IL258132A (en) A pharmaceutical composition containing a growth receptor agonist and an adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and its uses
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP3508482A4 (en) INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF
EP3694872A4 (en) T-CELL RECEPTORS FOR IMMUNOTHERAPY
IL258126B (en) A pharmaceutical composition containing a growth receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and its uses
EP3376870A4 (en) PROCESS FOR PREPARING KINASE INHIBITORS AND INTERMEDIATES THEREOF
EP3181487A4 (en) Discharge outlet fixing clamp for medium-sized bulk containers
ZA202002041B (en) Epidermal growth factor receptor inhibitors
EP3247360A4 (en) Heterocyclic inhibitors of monocarboxylate transporters
SI3172207T1 (sl) Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
EP3137447A4 (en) Inhibitors of creatine transport and uses thereof
IL290109A (en) Cells for enhanced immune healing and their uses
EP3313396A4 (en) G-PROTEIN-COUPLED RECEPTOR CINASE INHIBITORS AND METHOD OF USE THEREOF
IL258128A (en) A pharmaceutical composition containing a growth receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and its uses
EP3137100A4 (en) Isolated t cell receptors and methods of use therefor
EP3154577A4 (en) Oral composition and methods for immunotherapy
EP3154460A4 (en) High pressure remote delivery system for cement and methods of use
SG11201703550SA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
EP3459874C0 (de) Flächiges gebilde für einen biogasspeicher